- Home
- FORA vs CTSO Comparison
FORA vs CTSO Comparison
Compare FORA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- CTSO
- Stock Information
- Founded
- FORA 2014
- CTSO 1997
- Country
- FORA United States
- CTSO United States
- Employees
- FORA N/A
- CTSO N/A
- Industry
- FORA Computer Software: Prepackaged Software
- CTSO Medical/Dental Instruments
- Sector
- FORA Technology
- CTSO Health Care
- Exchange
- FORA Nasdaq
- CTSO Nasdaq
- Market Cap
- FORA 62.7M
- CTSO 68.2M
- IPO Year
- FORA N/A
- CTSO N/A
- Fundamental
- Price
- FORA $1.99
- CTSO $0.90
- Analyst Decision
- FORA Strong Buy
- CTSO Strong Buy
- Analyst Count
- FORA 1
- CTSO 3
- Target Price
- FORA $5.00
- CTSO $4.67
- AVG Volume (30 Days)
- FORA 27.4K
- CTSO 138.7K
- Earning Date
- FORA 05-16-2025
- CTSO 05-14-2025
- Dividend Yield
- FORA N/A
- CTSO N/A
- EPS Growth
- FORA N/A
- CTSO N/A
- EPS
- FORA N/A
- CTSO N/A
- Revenue
- FORA $20,153,263.00
- CTSO $35,594,520.00
- Revenue This Year
- FORA $13.31
- CTSO $18.72
- Revenue Next Year
- FORA N/A
- CTSO $19.75
- P/E Ratio
- FORA N/A
- CTSO N/A
- Revenue Growth
- FORA N/A
- CTSO 14.51
- 52 Week Low
- FORA $1.85
- CTSO $0.70
- 52 Week High
- FORA $4.03
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- FORA 49.09
- CTSO 37.43
- Support Level
- FORA $1.93
- CTSO $0.87
- Resistance Level
- FORA $2.11
- CTSO $1.16
- Average True Range (ATR)
- FORA 0.12
- CTSO 0.06
- MACD
- FORA 0.00
- CTSO -0.02
- Stochastic Oscillator
- FORA 34.75
- CTSO 7.79
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.